Baricitinib as a Treatment for Myasthenia Gravis: A Case Report

This case report describes a 58-year-old woman with ocular myasthenia gravis (MG) and alopecia areata who was treated with baricitinib, a JAK1/JAK2 inhibitor. The patient had not responded adequately to steroids and pyridostigmine. Over six months of baricitinib treatment, her MG symptoms completely resolved, and her hair regrew, even as steroids were tapered and pyridostigmine was discontinued. Additionally, the anti-acetylcholine receptor antibody titer decreased. This case suggests that JAK inhibitors like baricitinib may be effective in treating MG, particularly in patients resistant to conventional therapies.